| Subject: | FDA Clarifies Approved Conditions For Use Of ESAs In Patients With Cancer And Revises Dosing Directions |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Thu, 31 Jul 2008 - 03:00 pm |
| Amgen and FDA informed healthcare professionals of modifications to certain sections of the Boxed Warnings, Indications and Usage, and Dosage and Administration sections of prescribing information for Erythropoiesis Stimulating Agents (ESAs) (Procrit, Epogen, and Aranesp). The changes clarify the FDA-approved conditions for use of ESAs in patients with cancer and revises directions for dosing to state the hemoglobin level at which treatment with an ESA should be initiated. Additional revisions... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
With over 20 years experience in regulatory compliance, MCN Healthcare brings you the most comprehensive regulatory compliance tool available. StayAlert! is the only comprehensive e-mail notification service available that not only notifies you of the changes in major federal regulations, but also provides the policies, procedures, tools and best practices to help you meet the changing regulation. StayAlert! actively monitors TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others so you don't have to. Currently StayAlert! is the leader in the comprehensive compliance information marketplace. Why? Because StayAlert! provides healthcare professionals with more than information. StayAlert! provides a service, in many cases "doing the work" for you, and assisting regulatory compliance officers to effectively and efficiently meet changing standards. |
|
